{"name":"Orphalan","slug":"orphalan","ticker":"","exchange":"","domain":"","description":"Orphalan S.A. is an orphan drug development and commercialization company headquartered in Paris, France. It specializes in the development of treatments for patients with Rare diseases.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"TETA 4HCl formulation","genericName":"TETA 4HCl formulation","slug":"teta-4hcl-formulation","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"},{"name":"TETA 4HCL (60-<W108)","genericName":"TETA 4HCL (60-<W108)","slug":"teta-4hcl-60-w108","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"},{"name":"TETA 4HCL (W12-60)","genericName":"TETA 4HCL (W12-60)","slug":"teta-4hcl-w12-60","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"D-Penicillamine","genericName":"D-Penicillamine","slug":"d-penicillamine","indication":"Wilson's disease (copper accumulation)","status":"marketed"},{"name":"Penicillamine (W12-W60)","genericName":"Penicillamine (W12-W60)","slug":"penicillamine-w12-w60","indication":"Wilson's disease (copper accumulation disorder)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Penicillamine (D1-W12)","genericName":"Penicillamine (D1-W12)","slug":"penicillamine-d1-w12","indication":"Wilson's disease (copper accumulation disorder)","status":"phase_3"}]}],"pipeline":[{"name":"TETA 4HCl formulation","genericName":"TETA 4HCl formulation","slug":"teta-4hcl-formulation","phase":"phase_3","mechanism":"TETA 4HCl formulation is a tetraethylammonium chloride, a potassium channel blocker.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"D-Penicillamine","genericName":"D-Penicillamine","slug":"d-penicillamine","phase":"marketed","mechanism":"D-Penicillamine is a chelating agent that binds to heavy metals and promotes their urinary excretion, while also modulating immune function through reduction of disulfide bonds.","indications":["Wilson's disease (copper accumulation)","Rheumatoid arthritis","Cystinuria","Heavy metal poisoning (mercury, lead)"],"catalyst":""},{"name":"Penicillamine (D1-W12)","genericName":"Penicillamine (D1-W12)","slug":"penicillamine-d1-w12","phase":"phase_3","mechanism":"Penicillamine is a chelating agent that binds to heavy metals and promotes their urinary excretion, reducing toxic metal accumulation in tissues.","indications":["Wilson's disease (copper accumulation disorder)","Cystinuria (cystine stone prevention)"],"catalyst":""},{"name":"Penicillamine (W12-W60)","genericName":"Penicillamine (W12-W60)","slug":"penicillamine-w12-w60","phase":"phase_3","mechanism":"Penicillamine is a chelating agent that binds to heavy metals and promotes their urinary excretion, while also modulating immune responses through effects on collagen cross-linking and T-cell function.","indications":["Wilson's disease (copper accumulation disorder)","Cystinuria (amino acid metabolism disorder)","Rheumatoid arthritis (historical use)"],"catalyst":""},{"name":"TETA 4HCL (60-<W108)","genericName":"TETA 4HCL (60-<W108)","slug":"teta-4hcl-60-w108","phase":"phase_3","mechanism":"TETA 4HCL is a tetraethylammonium chloride, a potassium channel blocker.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"TETA 4HCL (W12-60)","genericName":"TETA 4HCL (W12-60)","slug":"teta-4hcl-w12-60","phase":"phase_3","mechanism":"TETA 4HCL (W12-60) is a tetraethylammonium chloride, a potassium channel blocker.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQdGZEZkxSSUtLdDQwZENseFRvQzdtcE9aenlMVFpoaVhDMjE2V0toYkUyOFhReEpKb2JSakJJMmI0dmc0Y2tJczFzcGF4WUhfeWRfZ2E3ay1SOHJpU2RpZ05ScmcxMENVc3pGQ3ZLMUtRUTRwbE1RR0EwTXZsSy1aM0c4cnR0VzV0TmdzZGVWUWxVRXM2MVg1VUY3ZmZUdDBaZDFVX2dxSkQ0by1kNkdkSnpyN05WUzJzVlJFVWhOSUhzWUp1Vmg4R2dxcUtQRXQ4VklnM0RYYng2ajNJSnNRR2xlZ1VWc19TQ2l5U3JJbnhiMW8?oc=5","date":"2025-12-15","type":"deal","source":"investorsinhealthcare.com","summary":"France: Orphalan acquires Orphelia Pharma to strengthen global commercial footprint in rare diseases - investorsinhealthcare.com","headline":"France: Orphalan acquires Orphelia Pharma to strengthen global commercial footprint in rare diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxObzVhTnBSMjViTFhxRk9SYlB2TExWc0RZNVJ5cDFQZW1KY2NtU2lhMUhYVndHZXU4NjBESS1zN0hRYks1bF9KTllBTkh0ZVY5NUNvVlFwVTZ2TXdRY3ZlTXlFRFNFYUV5R1pLLTFDWGhjR09TdWZyVnpXdXdiemR4cVNXeVZYUlNscUVFcVoyLXhMY0hNX2Fxb0s4S1ZnSE1GclBWandpVFFLTTFLSXBsLV9xVFFxU3F4LVRaUHhueER2WEpBN3A5Z3pNT180eEhpbTdFWmpSNA?oc=5","date":"2025-03-07","type":"pipeline","source":"PR Newswire","summary":"Orphalan becomes the first European company to enter in China's Wilson Disease market - PR Newswire","headline":"Orphalan becomes the first European company to enter in China's Wilson Disease market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNRkxqS0g2aHZGSmVSOXRMNjNzRFpMMnI3T3hzOVNIa2hfNndGX05PMGd4d09jMXlTT2hiVElRSEg5VVV1dmgxQzh3MlRUVWRsYjVFaFRtQUx0QU9McDJFSUh1eWFBNlNLRjVFeDFNZDJHdUtJdjMtZU5zdDYyblp3Q2VlTE1DLU5tYkV0c0dBeTFnOXBqRjBXWHprNlFxYU45c2RZQWZXRks4Q1VXampTMnhJSndhMEhZQW9odFBQbjJXMm5SNzFGUGh0cjRCcUtYQ3FQYW8yRVV3UktBMnZFd1lTOGN2WHQ5cDlHOVBERWJhRnJxMmtqSXM3Rk8?oc=5","date":"2025-02-14","type":"pipeline","source":"BioSpace","summary":"Wilson Disease Market Size to Reach USD 440.2 Million by 2035, Impelled by Surging Prevalence with Advanced Diagnostic Techniques - BioSpace","headline":"Wilson Disease Market Size to Reach USD 440.2 Million by 2035, Impelled by Surging Prevalence with Advanced Diagnostic T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMGMyc3FzZWVFdzhRRnlOeDZYdzFtMGRPemlzZEM5cFIwT0RJX3NWX1Y5NjRJS2E0N05uYTRKUEl1by1FalpUNGdqMncxRjBBLXlmM0xwTXdPUjR3SnNoc0xZU2pUb2tEdVVybXZTc05ORU8xSF9acUdISElEZHk0Q3dKc2dlWkRMUmpsUW5CN3NNYWFnNkg4WVp5clVCRGY0QTFqSS01LThaNGlhWFoxbVpVOHFBVnFq?oc=5","date":"2024-10-04","type":"pipeline","source":"Fierce Biotech","summary":"Ultragenyx tweaks gene therapy dosing to dial up efficacy after seeing signs of activity - Fierce Biotech","headline":"Ultragenyx tweaks gene therapy dosing to dial up efficacy after seeing signs of activity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNZVhIbXhlUUlKTkd1ODVhVjNVQmJGcWVsX3pOYzN0OUNLb1VDZjZtLXFSRzZXZkEyLVd5VEZtdDVYeV93Mm9TYlFvSTdqc05ScnFidUNlbEhHaUVjNkRwblpwZUhDM3RPRm1ETk5DZmg2RkxmUktwSTlZWllpTEFRVFpiamJ3Z0Njbi0wVHRYZThNZmd1VDUyUU9zb3pGcW1RSm9aemwtSmNNcGEtc0JGeEdUdk1aUHBLYXlvd0tsV2RQT3lBWHhyOV9fODNhR2V6Z21DY2wyZVpLVTZnSzNzRURYTXdsUV9RUTExMVI2Mnh6cFdaamc?oc=5","date":"2024-09-24","type":"pipeline","source":"European Medical Journal","summary":"Progressive Familial Intrahepatic Cholestasis in Adulthood: Genetics, Diagnosis, Treatment, and Further Research - European Medical Journal","headline":"Progressive Familial Intrahepatic Cholestasis in Adulthood: Genetics, Diagnosis, Treatment, and Further Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPUGlZNzRqNjhsdlBjQ2lPMy1FaTdseTllWVhxSkRSWllObVZXUVI5WjBXTzk0NC0wcHQ2Zkt3RzRHT3lyWEcyWE1HbUp3cnlxYmxMdkdPTWFkQ2NvS2FGdThiRVhQSVlZdE10YTZaMEYtLUg3dUxlUk51WkJCcGZIWFV4R19hWmxLTjU1YVBQaFktQQ?oc=5","date":"2023-04-21","type":"pipeline","source":"Pharmaceutical Technology","summary":"Orphalan launches Wilson disease therapy in US - Pharmaceutical Technology","headline":"Orphalan launches Wilson disease therapy in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOYkxLbG1FbGpxRGRFaVRtT0s4S3pFOE02d2h4b3pzTC0xbWZoN0ZPUTkxYXlkYURUVHRoSjNWZmNaX2h1NGNRR2dsLWdwcmNoeFFhemt3QXNtZTczajVtUlNDbV9jTTlhMm5VZ3NGR29lUmRabUtaRlBwbVFOM3NhcWlB?oc=5","date":"2023-04-21","type":"pipeline","source":"Labiotech.eu","summary":"Orphalan announces U.S. launch of drug to treat Wilson disease - Labiotech.eu","headline":"Orphalan announces U.S. launch of drug to treat Wilson disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPcWg4R3JYMUR0WnVUYWNsa2JPc2I5U3hNQjBCZ0w5YnBmZktoNG9Ka2dqdmdNekJPeWZBcFNCaXJjWWlUMWVsR2ZyQUpoZ2tQaUJ4YnRUbU8wanhSc3hzS0hDeWg1Q1BETHRCN0JaaUhLcG15SVBZRVUxVEVveG1Ka2JTME5pOHQ0dTdWUS04T2Fyd0NpdV9fcm11Slc0QWpWWGdac3F3ekNJRi1p?oc=5","date":"2022-05-02","type":"regulatory","source":"Fierce Pharma","summary":"Orphalan pushes first drug for Wilson's disease in 5 decades over FDA finish line - Fierce Pharma","headline":"Orphalan pushes first drug for Wilson's disease in 5 decades over FDA finish line","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOUDZqUDZoN293c2o0QUJaeW1kOVZsSG9KLWs3Q2xGN29pMEZIOW5jRFUyd2NscmpIeDJEN2VwSU1Pc2o0TzFfcHRuWV9YUGZkeDJlVmVLR0FpX01fNUxGcG4xZUllU3ROVlI4c0lsTWlTaW42VU9ncHJvYjV1cDBrcVZmV0ZkQ3EyTUprVTZtbTRQVm85X3pvRjBqNTllUjg?oc=5","date":"2022-05-02","type":"regulatory","source":"PharmaLive","summary":"Orphalan Touts First FDA-Approved Wilson’s Disease Treatment Since 1970 - PharmaLive","headline":"Orphalan Touts First FDA-Approved Wilson’s Disease Treatment Since 1970","sentiment":"positive"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":5,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}